Patent · US Active

Probenecid for use in treating epileptic diseases, disorders or conditions

US12318358B2 · kind B2 · utility

0Cited by

18References

13Claims

0Family size

Assignees

PARIS SCIENCES ET LETTRES
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
Sorbonne Universite · FR
APHP (ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS) · FR
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES · FR
UNIVERSITÉ PARIS CITÉ · FR

Inventors

Nathalie ROUACH · Paris, FR
Eléna DOSSI · Boulogne-Billancourt, FR
Gilles HUBERFELD · Garches, FR

Key dates

Filing date	Jul 13, 2018
Grant date	Jun 3, 2025
Priority date	—
Expiry date	Dec 2, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/0053
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in the subject. Preferably, the neurological disorder is an epileptic disease, disorder or condition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.